Effect of CRRT on the pharmacokinetics of meropenem and precision medicine in ICU sepsis patients

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026144

Enrollment

Unknown

Registered

2019-09-23

Start date

2019-09-30

Completion date

Unknown

Last updated

2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Meropenem anti-infective group:Anti-infective with meropenem

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Sepsis patients hospitalized in the ICU who were treated with renal replacement therapy (CRRT) while using meropenem to fight infection; 2. Aged greater than 18 years. There are no restrictions on gender, body weight, primary disease or underlying disease, comorbidities, liver and kidney function, and other organ functions (including antibiotics); 3. Patients need to use meropenem for anti-infective treatment for clinical treatment, and the course of treatment is expected to be at least 3 days.

Exclusion criteria

Exclusion criteria: The clinician judges that the patient is not eligible for inclusion in the study.

Design outcomes

Primary

Measure	Time frame
Meropenem plasma concentration;	—

Countries

China

Contacts

Public ContactQi Pei

Department of Pharmacy, the Third Xiangya Hospital, Central South University

peiqi1028@126.com+86 13170419804

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026